• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Widowmaker: Stents as safe as open heart surgery in left main artery disease

Widowmaker: Stents as safe as open heart surgery in left main artery disease

April 3, 2015 By Val Kennedy

heart stent

A long-term Korean study found stents as safe as open heart surgery in treating blockages of a coronary artery known as the widowmaker, showing that stented patients did not run a significantly higher risk of suffering a heart attack or stroke.

But patients who underwent percutaneous coronary intervention, or angioplasty, with sirolimus-eluting stents were more likely to require revascularization than patients given coronary artery bypass grafts.

The randomized study, sponsored by Korea’s Cardiovascular Research Foundation, tracked approximately 600 cardiac patients for 5 years after they underwent either stenting or CABG for treatment of left main coronary artery disease. Patients in the stent cohort were treated with Johnson & Johnson’s (NYSE:JNJ) Cypher sirolimus-eluting stent.

Five-year results from the Precombat study were published last month in the Journal of the American College of Cardiology.

The study showed that 17.5% of PCI patients experienced a major adverse cardiac or cerebrovascular event within 5 years, compared with 14.3% of CABG patients. The rate of death, stroke or heart attack was 8.4% for the PCI group versus 9.6% for CABG patients.

Stent recipients had a significantly higher rate of revascularization. The rate of ischemia-driven target vessel revascularization was 11.4% for stent recipients versus 5.5% for the CABG group.

“During 5-year follow-up, our study did not show significant difference regarding the rate of MACCE between patients who underwent PCI with a sirolimus-eluting stent and those who underwent CABG. However, considering the limited power of our study, our results should be interpreted with caution,” the researchers wrote.

Data from the study were presented last month during a scientific session at the American College of Cardiology’s annual meeting.

“It’s an impressive study in terms of completeness of follow-up [and excellence of the operators] and shows that … left main stenting does have quite similar outcomes to bypass surgery,” the session’s moderator, Dr. John Carroll, told heartwire. “However, it doesn’t help us decide in an individual patient which is the best route to go, [and] the surgical group may not have had the same intensity of medical therapy.”

Filed Under: Drug-Eluting Stents, News Well Tagged With: American College of Cardiology, Clinical Trials, Korean Cardiovascular Research Foundation

More recent news

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • Ancora Heart reaches enrollment milestone in pivotal heart failure device trial
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Johnson & Johnson launches daily disposable multifocal toric contact lens
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy